Search filters

Filters
Clear All

Phase

  • 67
  • 68
  • 1
  • 81
  • 60
  • 13
  • 190
  • 556
  • 217
  • 9
  • 22
  • 528
  • 556
  • 3

Found 559 Barrett's Esophagus trials

A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
18 years - 99 years
Accepts healthy volunteer
All genders
Phase 3
The research study is being conducted to study the effectiveness of the mRNA-1273 study vaccine in people who have received a kidney or liver transplant. Healthy participants are being included in the study to compare the results from these participants to those who have had a kidney or liver transplant. …
 Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)
17 years - 75 years
All genders
Interventional
This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after …
18 years - 99 years
All genders
Interventional
The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of …
18 years - 99 years
All genders
Phase 3
Interventional
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total …
99 years or below
All genders
This protocol is an 18-month, multicenter, randomized, double-blind, placebo-controlled, phase 2 study comparing 1400 mg of donanemab versus placebo over 76 weeks in approximately 500 patients with early symptomatic AD. Study duration including screening and post treatment is up to 133 weeks. Study drug will be prepared and stored at …
99 years or below
All genders
This study is designed to evaluate the efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. Adults with psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) will be enrolled. The study involves data and …
99 years or below
All genders
Subjects with unusual lipids in subjects with known or suspected genetic variants that may be associated with change in lipoprotein kinetics will have two-night, one-day inpatient stay in CHPS, during which they will undergo extensive evaluation of lipoprotein kinetics using stable isotope techniques, OFTT, and OGTT. Subjects will complete a …
 Cycled Phototherapy: A Safer Effective Method to Control
99 years or below
All genders
Phase 3
This is a pragmatic, randomized, clinical trial addressing patient safety. The proposed trial is a minimal-risk safety trial in which extremely premature infants (less than or equal to 750 birth weight and/or less than 27 weeks gestational age) would be randomized to either a continuous phototherapy regimen or to the …
 Glioblastoma adaptive  global  innovative learning environment
18 years - 99 years
All genders
Phase 2
This research study aims to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma …
 A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 2
Interventional
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
181 - 190 of 559